Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma
Liu, B.; Kuang, A.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 29(3): 588-592
2012
ISSN/ISBN: 1001-5515 PMID: 22826964 Document Number: 656446
Traditionally, during the follow-up and in order to receive 131 I therapy, patients with differentiated thyroid carcinoma (DTC) have to withdraw from using thyroid hormone. The hypothyroidism induced by hormone withdrawal can negatively affect the quality-of-life (QOL) of DTC patients. Without the hormone withdrawal, recombinant human thyroid-stimulating hormone-aided management of DTC patients can effectively obviate the consequences of hypothyroidism. This review will focus on the clinical application of recombinant human thyroid-stimulating hormone (rhTSH) in the management of DTC patients.